GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
At the 2016 Annual Meeting of Stockholders held on December15,
2016, the stockholders of Galectin Therapeutics Inc. (Galectin or
the Company) re-elected each of the Companys directors that had
been nominated to serve until the next annual meeting or until
their successors are elected and have been qualified. The
stockholders also voted on a non-binding advisory resolution to
approve the compensation paid to the Companys named executive
officers and ratified the selection of Cherry Bekaert LLP as the
independent registered public accounting firm for the Company for
the year ending December31, 2016.
The final results of the voting on each matter of business at the
2016 Annual Meeting are as follows:
Election of Directors
|
Name |
VotesFor |
VotesWithheld |
BrokerNon-Votes |
|||||||||
|
Gilbert F. Amelio, Ph.D. |
10,677,510 | 573,344 | 14,976,838 | |||||||||
|
Kevin D. Freeman |
11,003,268 | 247,586 | 14,976,838 | |||||||||
|
Arthur R. Greenberg |
10,826,611 | 424,243 | 14,976,838 | |||||||||
|
John Mauldin |
10,692,692 | 558,162 | 14,976,838 | |||||||||
|
Gilbert S. Omenn, M.D., Ph.D. |
10,869,940 | 380,914 | 14,976,838 | |||||||||
|
Steven Prelack |
10,878,337 | 372,517 | 14,976,838 | |||||||||
|
Marc Rubin, M.D. |
10,870,558 | 380,296 | 14,976,838 | |||||||||
|
Peter G. Traber, M.D. |
10,844,660 | 406,194 | 14,976,838 |
Non-binding advisory resolution to approve the compensation
paid to the Companys named executive officers
|
Votes For |
Votes Against |
Votes Abstain |
Broker Non-Votes |
|||
|
10,263,034 |
844,997 | 142,823 | 14,976,838 |
Ratification of the selection of Cherry Bekaert LLP as the
independent registered public accounting firm for the Company for
the year ending December31, 2016
|
Votes For |
Votes Against |
Votes Abstain |
||
|
25,457,842 |
533,163 | 236,687 |
Additionally, the holder of the Companys Series B Convertible
Preferred Stock voted as a separate class to nominate and elect
two directors (the Series B Directors). Mr.James Czirr was
re-elected as a Series B Director and Dr.Theodore Zucconi was
elected as a new Series B Director, each to serve until the next
annual meeting or until their successors are elected and have
been qualified. The results of the voting for the Series B
Directors are as follows:
|
Name |
Votes For |
Votes Withheld |
Broker Non-Votes |
|||
|
James C. Czirr |
6,356,932 | n/a | ||||
|
Theodore Zucconi |
6,356,932 | n/a |
About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)
